AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 586-600

  Bierhaus, Angelika ^a   Hofmann, Marion A ^a   Ziegler, Reinhard ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced glycation endproducts; Diabetes mellitus; Vascular disease

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; PROTEIN; THIOCTIC ACID; TRANSCRIPTION FACTOR;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOOXIDATION; CHEMICAL MODIFICATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; GENE EXPRESSION; GLYCATION; KIDNEY DISEASE; OXIDATION; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN LIPID INTERACTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; MAILLARD REACTION; VASCULAR DISEASES;

EID: 0032029363     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00233-2     Document Type: Review

References (167)

1. [1] Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nature Med 1995;1:1002-1004.
2. [2] Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological and clinical implications for diabetes and aging. Lab Invest 1994;70:138-151.
3. [3] Wu JT. Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal 1993;7:252-255.
4. [4] Brownlee M, Cerami A, Vlassara H. Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
5. [5] Vlassara H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 1984;160:197-207.
6. [6] Maillard LC. Action des acides amines sur les sucres; formation des melanoides par voie methodique. CR Acad Sci 1912;154:66.
7. [7] Njorge FG, Monnier VM. The chemistry of the maillard reaction under physiological conditions: A review. Prog Clin Biol Res 1989;304:85-107.
8. [8] Reinauer H. Biochemistry of protein glycation in diabetes mellitus. Klin Lab 1993;39:984-987.
9. [9] Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N∈ (carboxymethyl)lysine is a dominant advanced glycation endproduct (AGE) antigen in tissue proteins. Biochemistry 1995;34:10873-10878.
10. [10] Bucala R, Vlassara H. Advanced glycation endproducts in diabetic renal and vascular disease. Am J Kidney Dis 1995;26:875-888.
11. [11] Acharaya AS, Manning JM. Reactions of glycerolaldehyde with proteins: latent crosslinking potential of α-hydroxyaldehydes. Proc Natl Acad Sci USA 1983;80:3590-3594.
12. [12] Bann HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981;213:222-224.
13. [13] Takagi Y, Kashiwagi A, Tanaka Y, Asahina T, Kikkawa R, Shigeta Y. Significance of fructose-induced protein oxidation and formation of advanced glycation end products. J Diabetes Complications 1995;9:87-91.
14. [14] Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzmatic glycation of bovine serun albumin by fructose (fructosylation): comparision with the Maillard reaction initiated by glucose. J Biol Chem 1989;264:3674-3679.
15. [15] Ahmed MU, Thorpe SR, Baynes JW. Identification of carboxymethyllysine as a degradation product of fructose-lysine in glycosylated protein. J Biol Chem 1986;261:4889-4994.
16. [16] Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxydation, and cross-linking of collagen by glucose. Kinetics, mechansims and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-683.
17. [17] Dyer D, Blackledge J, Thorpe S, Baynes J. Formation of pentosidine during nonenzymatic browning of proteins by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-11660.
18. [18] Dunn JA, Ahmed MU, Murtiashaw MH, Richardson JM, Walla M, Thorpe SR, Baynes JW. Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990;29:10964-10970.
19. [19] Glomb MA, Monnier V. Mechanism of protein modifications by glyoxal and glyceraldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-10026.
20. [20] Wolff SP, Dean RT. Glucose autoxidation and protein modification. Biochem J 1987;245:243-250.
21. [21] Nagaraj R, Monnier V. Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. Biochim Biophys Acta 1995;1253:75-84.
22. [22] Fu MX, Requena R, Jenkins A, Lyons T, Baynes JW, Thorpe SR. The advanced glycation end product, N∈(Carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-9986.
23. [23] Ledl F, Beck J, Sengl M, Osiander H, Estendorfer S, Severin T, Huber B. Chemical pathways of the Maillard reaction. Prog Clin Biol Res 1989;29:23-42.
24. [24] Ledl F. The decomposition of reducing sugars and amines in the Maillard reaction. Z Ernährungsw 1991;30:4-17.
25. [25] Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y. Modification of β2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996;49:861-867.
26. [26] Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995;34:3702-3709.
27. [27] Westwood ME, McLellan AC, Thornalley PJ. Receptor mediated endocytic uptake of methylglyoxal-modified serum albumin. J Biol Chem 1994;269:32293-32298.
28. [28] Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague Dawley rat. Diabetologia 1995;38:387-394.
29. [29] Hamada Y, Araki N, Horiuchi S, Hotta N. Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 1996;11(Suppl 5):95-98.
30. [30] Jiang ZY, Woolard ACS, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990;268:69-71.
31. [31] Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation: glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes and aging. Biochem J 1988;256:205-212.
32. [32] Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications. Diabetes 1990;39:1420-1424.
33. [33] Wells-Knecht M, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995;34:15134-15141.
34. [34] Stadtman ER, Berlett BS. Fenton chemistry: amino acid oxidation. J Biol Chem 1991;266:17201-17211.
35. [35] Chase KV, Carubelli R, Nordquist RE. The role of nonenzymatic glycosylation, transition metals, and free radicals in the formation of collagen aggregates. Arch Biochem Biophys 1991;288:473-480.
36. [36] Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.
37. [37] Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996;28:419-426.
38. [38] Takata K, Horiuchi S, Araki M, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988;263:14819-14825.
39. [39] Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morinho Y. Scavenger receptor of human leukemia cell line (THP-1) and murine macrophages for nonenzymatically glycosylated proteins. Biochim Biophys Acta 1989;986:18-26.
40. [40] Bailey AJ, Sims TJ, Avery NC, Miles CA. Chemistry of cross-links - glucose-mediated covalent crosslinikng of type-IV collagen in lens capsules. Biochem J 1993;296:489-496.
41. [41] Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of LDL by advanced glycosylation end-products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-9445.
42. [42] Vlassara H, Brownlee M, Cerami A. High affinity receptor mediated uptake and degradation of glucose modified proteins: a potential mechanism for the removal of senscent macromolecules. Proc Natl Acad Sci USA 1985;82:5588-5592.
43. [43] Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991;174:515-524.
44. [44] Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedmann EA, Cerami A, Vlassara H. Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
45. [45] Vlassara H. Advanced glycation in diabetic renal and vascular disease. Kidney Int 1995;48(Suppl 51):43-44.
46. [46] Monnier V. The Maillard reaction in aging, diabetes and nutrition. In: Baynes JW, Monnier V, editors. NIH conference, New York: A.R. Liss, 1988: 1-22.
47. [47] Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994;94:110-117.
48. [48] Kohn RR, Cerami A, Monnier VM. Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 1984;33:57-59.
49. [49] Yamagishi S-C, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. J Biol Chem 1997;272:8723-8730.
50. [50] Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE. Vascular hypertrophy in experimental diabetes - Role of advanced glycation end products. J Clin Invest 1997;99:1016-1027.
51. [51] Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708.
52. [52] Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991;174:931-939.
53. [53] Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992;89:2873-2877.
54. [54] Ducrocq R, Bachour H, Belkhodja R, Berriche S, Elion J. Evidence for nonenzymatic glycation of antithrombin III in diabetic patients. Clin Chem 1985;31:338-339.
55. [55] Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989;170:1387-1407.
56. [56] Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycation end product-modified proteins. J Clin Invest 1992;90:439-446.
57. [57] Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL1 induced by glucose-modified proteins: role in normal tissue remodelling. Science 1988;240:1546-1548.
58. [58] Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Stricker LJ. Advanced glycation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91:9436-9440.
59. [59] Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 1992;90:1110-1113.
60. [60] Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlassara H. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993;178:2165-2172.
61. [61] Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP. Advanced glycation endproducts (AGEs) mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262-2271.
62. [62] Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, Guillausseau PJ, Stern DM. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994;91:7742-7746.
63. [63] Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern DM. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995;96:1395-1403.
64. [64] Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995;1:447-456.
65. [65] Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induced transendothelial monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease and diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-9014.
66. [66] Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;91:2155-2168.
67. [67] Bucala R, Tracey KJ, Cerami A. Advanced glycation endproducts quench nitrite oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-438.
68. [68] Quehenberger P, Greten J, v-Riedesel J, Ziegler R, Wahl P, Speiser W, Bierhaus A, Nawroth PP. Endothelin-1 is under the control of the transcription factors p50/p65 (NF-κB) and AP-1. Ann Hematol 1995;70:211. A53 (abstr.).
69. [69] Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.
70. [70] Bierhaus A, Chevion S, Chevion M, Quehenberger P, Hofmann M, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP. Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by γ-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-1490.
71. [71] Dobrian A, Lazar V, Tirziu D, Simionescu M. Increased macrophage uptake of irreversibly glycated albumin modified-low density lipoproteins of normal and diabetic subjects is mediated by non-saturable mechanisms. Biochim Biophys Acta 1996;1317:5-14.
72. [72] Miyata S, Liu BP, Shoda H, Ohara T, Yamada H, Suzuki K, Kasuga M. Accumulation of pyrralidine modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J Biol Chem 1997;272:4037-4042.
73. [73] Bucala R, Model P, Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 1984;81:105-109.
74. [74] Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994;14:1521-1528.
75. [75] Koenig RJ, Blobstein SH, Cerami A. Structure of carbohydrate of hemoglobin A1c. J Biol Chem 1977;252:2992-2997.
76. [76] Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose hemoglobin A1c in diabetes mellitus. N Engl J Med 1976;295:417-420.
77. [77] Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992;258:651-653.
78. [78] Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
79. [79] Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of N-epsilon-(carboxymethyl)lysine and N-epsilon-(carboxymethyl)-hydroxylysine in human skin collagen. Biochemistry 1991;30:1205-1210.
80. [80] Dunn JA, Patrick JS, Thorpe SJ, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of Ne-(carboxymethyl)lysine in lens proteins. Biochemistry 1989;28:9464-9468.
81. [81] Knecht KJ, Dunn JA, McFarland KF, McCance DR, Lyons T, Thorpe SR, Baynes JW. Effect of diabetes and aging on carboxymethyllysine levels in human urine. Diabetes 1991;40:190-196.
82. [82] Miyata S, Monnier V. Immunhistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992;89:1102-1112.
83. [83] Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo. J Biol Chem 1989;263:3758-3764.
84. [84] Smith PR, Somani HH, Thornally PJ, Benn J, Sonksen PH. Evidence against the formation of 2-amino-6-(2-formyl-5-hydroxymethyl-pyrrol-1-yl)-hexanoid acid (pyrraline) as an early-stage product of advanced glycation end products in non-enzymatic protein glycation. Clin Sci 1992;84:87-93.
85. [85] Wells-Knecht KJ, Lyons TJ, R. MD, Thorpe SR, Feather MS, Baynes JW. 3-Deyoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 1994;443:1152-1156.
86. [86] Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M. Increase in 3-deoxyglucosone levels in diabetic rat plasma. J Biol Chem 1994;269:20275-20280.
87. [87] McLellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci Colch 1994;87:21-29.
88. [88] Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T, Nakagawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 1993;42:345-350.
89. [89] Radoff S, Makita Z, Vlassara H. Radioreceptor assay for advanced glycosylation end products. Diabetes 1991;40:1731-1738.
90. [90] Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 1992;267:5133-5138.
91. [91] Nakayama H, Taneda S, Kuwajima S, Aoki S, Kuroda Y, Misawa K, Nakagawa S. Production and characterisation of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989;162:740-745.
92. [92] Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;174:654-667.
93. [93] Berg TJ, Dahl-Jorgenson K, Torjesen PA, Hanssen KF. Increased serum levels of advanced glycation end products (AGEs) in children and adolescent with IDDM. Diabetes Care 1997;20:1006-1008.
94. [94] Nakayama Y, Horii Y, Nishino T. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-1656.
95. [95] Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 1995;26:308-313.
96. [96] Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunhistochemical localisation of advanced glycosylationend products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-1656.
97. [97] Mitsuhashi T, Nakayama H, Itoh T, Kuwajiama S, Aoki S, Atsumi T, Koike T. Immunhistochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 1993;42:826-832.
98. [98] Shikata K, Makino H, Sugimoto H, Kushiro M, Ota K, Akiyama K, Araki N, Horiuchi S, Ota Z. Localisation of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 1995;9:269-271.
99. [99] Gugliucci A, Bendayan M. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 1995;43:591-600.
100. [100] Makita Z, Yanagisawa K, Kuwajima S, Yoshioka N, Atsumi T, Hasunuma Y, Koike T. Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications 1995;9:265-268.
101. [101] Ritz E, Deppisch R, Nawroth P. Toxicity of uraemia - does it come of AGE?. Nephrol Dial Transplant 1994;9:1-2.
102. [102] Gugliucci A, Bendayan M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochim Biophys Res Commun 1995;212:56-62.
103. [103] Papoulis A, Youssef A, Bucala R. Identification of N2-(1-carboxy-ethyl) guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 1995;34:648-655.
104. [104] Vlassara H, Fuh H, Makita Z, Kungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992;89:12043-12047.
105. [105] Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) colocalize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997;150:523-539.
106. [106] Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 1996;92:747-750.
107. [107] Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T. β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
108. [108] Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?. NeuroReport 1995;6:866-868.
109. [109] Yan S-D, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, Stern DM. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat Med 1995;1:693-699.
110. [110] Takeda A, Yasuda T, Miyata T, Mizuno K, Li M, Yoneyama S, Horie K, Maeda K, Sobue G. Immunhistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996;221:17-20.
111. [111] Vitek MP, Bhattacharaya K, Glending JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766-4770.
112. [112] Münch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Research Reviews 1997;23:134-143.
113. [113] Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-176.
114. [114] Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994;91:5710-5714.
115. [115] Vlassara H, 'Meet the expert' lecture. Oral presentation; EASD meeting Vienna, 1996.
116. [116] Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990;173:932-939.
117. [117] Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A. Immunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl Thromb Vasc Biol 1995;15:571-582.
118. [118] Brownlee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the in situ formation of immuncomplexes. J Exp Med 1983;158:1739-1744.
119. [119] Makita Z, Bucala R, Rayfield EF, Friedmann EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. Diabetic-uremic serum advanced glycosylation endproducts are chemically reactive and resistant to dialysis therapy. Lancet 1994;343:1519-1522.
120. [120] Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston J, Fuh H, Manogue KR, Cerami A, Vlassara H. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519-1522.
121. [121] Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes. Proc Natl Acad Sci USA 1981;78:5190-5192.
122. [122] Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci 1995;129:62-68.
123. [123] Poduslo JF, Curran GL. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res Mol Brain Res 1994;23:157-162.
124. [124] Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991;88:11555-11558.
125. [125] Hammes H-P, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994;37:32-35.
126. [126] Yamagishi S, Hsu CC, Tanigucchi M, Harada S, Yamamoto Y, Ohsawa K, Kobayashi K, Yamamoto H. Receptor mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of percyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 1995;213:681-687.
127. [127] Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, Preissner KT. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 1996;75:325-338.
128. [128] Bellmunt MJ, Portero M, Pamplona R, Muntaner M, Prat J. Age-related fluorescense in rat lung collagen. Lung 1995;173:177-185.
129. [129] Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins). an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474-6479.
130. [130] Vlassara H. Pathogenesis of diabetic nephropathy, advanced glycation and new therapy. Med Klin 1997;92(Suppl 1):29-34.
131. [131] Baumgartl H-J, Hofmann H, Standl E. Erhöhung der Serum-AGEs ('advanced glycosylation endproducts') bei Rauchern unter den Typ-1-Diabetikern. Diab Stoffw 1996;5:151. (abstr.).
132. [132] Drickhammer K. Breaking the curse of the AGEs. Nature 1996;382:211-212.
133. [133] Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation endproduct inhibition by aminoguanidine. Diabetes 1992;41:26-29.
134. [134] Hirsch J, Baines CL, Feather MS. X-ray structures of a 3-amino-5-and a 3-amino-6-substituted triazine, producedas a result of reaction of 3-deoxy-D-erythrhexo-2-ulose (3-deoxyglucosone) with aminoguanidine. J Carbohydr Chem 1992;11:891-901.
135. [135] Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986;232:1629-1632.
136. [136] Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995;46:223-234.
137. [137] Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L. Prevention of diabetes-increased aging effect on rat collagen-linked flurescence by aminoguanidine and rutin. Diabetes 1990;39:796-801.
138. [138] Oxlund H, Andreassen TT. Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetolgia 1992;35:75-78.
139. [139] Hujiberts MSP, Wolffenbuttel BRH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Levy BI. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993;92:1407-1411.
140. [140] Picard S, Parthasarathy S, Fruebis J, Witzum JL. Aminoguanidine inhibits oxidative modifications of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1991;89:6876-6880.
141. [141] Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992;35:96-97.
142. [142] Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991;40:1016-1019.
143. [143] Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozocin-induced diabetic rats. Diabetes 1991;40:1328-1334.
144. [144] Nicholls K, Mandel TE. Advanced glycosylation endproducts in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 1989;60:486-491.
145. [145] Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetes rats. Diabetologia 1991;35:946-950.
146. [146] Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effects of aminoguanidine on functional and structural abnormalities in peripheral nerves of STZ-induced diabetic rats. Diabetes 1992;41:47-52.
147. [147] Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nicklander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygene free radicals. Proc Natl Acad Sci USA 1991;88:6107-6111.
148. [148] Lewis BS, Harding JJ. The effects of aminoguanidine on the glycation (nonenzymatic glycosylation) of lens proteins. Exp Eye Res 1990;50:463-467.
149. [149] Li Y-M, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996;93:3902-3907.
150. [150] Ou P, Wolff SP. Aminoguanidine: a drug proposed for the prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 1993;43:1139-1144.
151. [151] Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fuji W, Yanagisawa K, Kawata T, Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997;46:895-899.
152. [152] Munch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P. The cognition-enhancing drug Tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm 1994;8:193-208.
153. [153] Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997;138:1886-1892.
154. [154] Hipkiss AR, Michaelis J, Syrris P, Kumar S, Lam Y. Carnosine protects against in vitro glycation and cross-linking. Biochem Soc Trans 1994;2:399.
155. [155] Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-crosslinking agent. FEBS Lett 1995;371:81-85.
156. [156] Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275-278.
157. [157] Packer L, Witt EH. Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biol Med 1995;19:227-250.
158. [158] Godin DV, Wohaieb SA, Garnett ME, Goumeniouk AD. Antioxidant enzyme alterations in experimental and clinical diabetes. Mol Cell Biochem 1988;84:223-231.
159. [159] Thornally PJ, McLellan AC, Lo TW, Benn J, Sonksen PH. Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci Colch 1996;91:572-582.
160. [160] Forsberg H, Borg LA, Cagliero E, Eriksson UJ. Altered levels of scavenging enzymes in embryos subjected to a diabetic environment. Free Radic Res 1996;24:451-459.
161. [161] Laaksonen DE, Atalay M, Niskanen L, Uusitupa M, Hanninen O, Sen CK. Increased resting and exercise-induced oxidative stress in young IDDM men. Diabetes Care 1996;19:569-574.
162. [162] Akkus I, Kalak S, Vural H, Caglayan O, Menekse E, Can G, Durmus B. Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels in patients with type II diabetes mellitus. Clin Chim Acta 1996;244:221-227.
163. [163] Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radical Biol Med 1991;10:339-352.
164. [164] Thorpe S, Baynes J. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69-77.
165. [165] Swamy MS, Abraham EC. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest Ophtalmol 1989;30:1120-1126.
166. [166] Aoki Y, Yanagisawa Y, Yazaki K, Oguchi H, Kiyosawa K, Furuta S. Protective effect of vitamin E supplementation on increased thermal stability of collagen in diabetic rats. Diabetologia 1992;35:913-916.
167. [167] Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996;97:1422-1428.